云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

已收盘 06-09 16:08:13

27.520

-0.440

-1.57%

最高28.380	最低26.960	成交量348.16万
今开28.300	昨收27.960	日振幅5.08%
总市值97.42亿	流通市值97.42亿	总股本3.54亿
成交额9,631万	换手率0.98%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":27.52,"timestamp":1780992493003,"preClose":27.96,"halted":0,"volume":3481600,"delay":0,"changeRate":-0.015736766809728228,"floatShares":354000000,"shares":354000000,"eps":-1.0301405106342962,"marketStatus":"已收盘","change":-0.44,"latestTime":"06-09 16:08:13","open":28.3,"high":28.38,"low":26.96,"amount":96311117,"amplitude":0.050787,"askPrice":27.52,"askSize":16500,"bidPrice":27.48,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-1.0787538830462517,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781055000000},"marketStatusCode":5,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":27.96,"openAndCloseTimeList":[[1780968600000,1780977600000],[1780981200000,1780992000000]],"volumeRatio":0.789542,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2641171090","title":"云顶新耀获董事会主席吴以芳增持2万股 每股作价28.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641171090","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641171090?lang=zh_cn&edition=full","pubTime":"2026-06-08 07:58","pubTimestamp":1780876680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，6月4日，董事会主席吴以芳增持云顶新耀（01952）2万股，每股作价28.8港元，总金额为57.6万港元。增持后最新持股数目约为216.02万股，最新持股比例为0.61%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-08/doc-iniarzfy7258720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01952","EWH","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116171","title":"云顶新耀(01952)与箕星订立在大中华区开发及商业化LNZ100的协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116171","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116171?lang=zh_cn&edition=full","pubTime":"2026-06-08 06:59","pubTimestamp":1780873199,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，于2026年6月5日，本公司与箕星药业有限公司(箕星)的全资附属公司箕星药业香港有限公司订立协议(该协议)，箕星药业香港有限公司不可撤销地向本公司授予一项独家许可，以在大中华区开发、生产及商业化LNZ100。在中国，LNZ100的新药上市申请已于2025年9月提交，预计将于2027年第一季度获得批准。该疗法有潜力解决中国巨大的未满足医疗需求，并将自身定位为老花眼治疗的同类最佳无创治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)与箕星订立在大中华区开发及商业化LNZ100的协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641214854","title":"董事会主席吴以芳增持云顶新耀(01952)2万股 每股作价28.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641214854","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641214854?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:20","pubTimestamp":1780662037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月4日，董事会主席吴以芳增持云顶新耀(01952)2万股，每股作价28.8港元，总金额为57.6万港元。增持后最新持股数目约为216.02万股，最新持股比例为0.61%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","BK1574","EWH","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640363691","title":"【券商聚焦】交银国际维持云顶新耀(01952)买入评级 指肾科潜在重磅单品成功BD出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2640363691","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640363691?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:20","pubTimestamp":1780539615,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，云顶新耀 近日宣布与Travere Therapeutics达成许可合作协议，将EVER001的全球权益首予后者，并将获得1.125亿美元首付款、最高10.3亿美元的里程碑付款及高单位数至双位数百分比的销售分成。Travere是一家专注于肾病领域的生物制药公司，其核心产品FILSPARI已在美国、欧洲等多个市场获批上市。该机构认为，FILSPARI的成功开发及上市充分体现Travere在肾病领域的深厚专业经验及临床研发、监管事务与商业化能力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983013","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143732465","title":"CBC集团斥资2000万港元购入云顶新耀69万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1143732465","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143732465?lang=zh_cn&edition=full","pubTime":"2026-06-04 07:37","pubTimestamp":1780529854,"startTime":"0","endTime":"0","summary":"6月4日（路透社）—— 云顶新耀有限公司宣布，CBC集团以每股28.93港元的价格，购入该公司69万股股份，总交易金额达2000万港元。\n此次交易进一步凸显了投资者对云顶新耀的关注与信心。每股价格明确为28.93港元，为市场提供了清晰的参考信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640187727","title":"云顶新耀(01952)获公司主要股东增持69万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640187727","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640187727?lang=zh_cn&edition=full","pubTime":"2026-06-04 07:05","pubTimestamp":1780527923,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，公司董事会获非执行董事、董事会荣誉主席兼公司主要股东傅唯先生告知，于2026年6月3日，康桥资本于市场购入69万股公司普通股，总代价约为2000万港元，平均价格约为每股股份28.93港元。据傅唯先生及康桥资本表示，其透过场内收购方式购入股份，乃基于其对公司未来前景及长远发展的坚定信心。在遵守适用法律及法规的前提下，傅唯先生及康桥资本不排除在适当时候进一步增持其于公司股份的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)获公司主要股东增持69万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183580193","title":"CBC集团以每股28.93港元购入69万股云顶新耀股份，涉资约2000万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183580193","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183580193?lang=zh_cn&edition=full","pubTime":"2026-06-04 07:03","pubTimestamp":1780527794,"startTime":"0","endTime":"0","summary":"CBC集团近日完成一笔对云顶新耀（01952.HK）的股份收购，以每股28.93港元的价格购入69万股，总交易金额约为2000万港元。此次交易显示出市场对云顶新耀的关注与投资信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116117432","title":"云顶新耀发布2026年5月股份变动月报表，新增112,601股","url":"https://stock-news.laohu8.com/highlight/detail?id=1116117432","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116117432?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:22","pubTimestamp":1780485740,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司于2026年6月3日发布截至2026年5月31日止的股份变动月报表，披露截至报告期末公司普通股与注册资本等情况。根据公告，公司法定/注册股本维持为500,000,000股，对应注册股本为USD 50,000，与上月一致，未发生变化。公司确认其公众持股量已达上市规则要求。库存股份数量保持为零，未见回购或注销新增情况。公司方面确认了所有增发及股权激励授予均符合香港联交所《上市规则》和相关法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640756219","title":"先买后卖 云顶新耀一笔授权交易首付款赚了8倍多","url":"https://stock-news.laohu8.com/highlight/detail?id=2640756219","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640756219?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:14","pubTimestamp":1780463643,"startTime":"0","endTime":"0","summary":"【先买后卖 云顶新耀一笔授权交易首付款赚了8倍多】中国本土药企的对外授权交易热潮持续。6月1日晚间，云顶新耀（01952.HK）宣布与纳斯达克企业Travere Therapeutics达成独家授权许可与合作协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606033758819289.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606033758819289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01952","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640792739","title":"港股异动 | 云顶新耀(01952)高开近5% 向Travere授予独家授权以开发和商业化civorebrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640792739","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640792739?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:25","pubTimestamp":1780449927,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀高开近5%，截至发稿，涨4.71%，报31.12港元，成交额227.18万港元。消息面上，云顶新耀发布公告，于2026年6月2日，公司全资附属公司Everest Medicines  Pte.Ltd.(授权人)与Travere Therapeutics,Inc.订立独家许可与合作协议，据此，授权人将向Travere授予一项独家、全球性的授权，以开发及商业化civorebrutinib。交割将于满足特定先决条件及监管程序后发生，授权人最终达成的里程碑付款金额仍存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK4588","BK1161","BK1574","BK4585","VXUS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173973650","title":"云顶新耀授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1173973650","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173973650?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:17","pubTimestamp":1780409824,"startTime":"0","endTime":"0","summary":"云顶新耀发布公告，将于2026年6月26日（星期五）上午9时30分召开股东周年大会，通过虚拟会议形式审议并批准一项股份购回授权。该授权如获股东大会通过，董事会可于适用法律及公司组织章程规定的期限内，回购最多相当于公司于股东大会当日已发行股本10%的股份。若获全面行使，此次购回授权的最高规模合计达35,379,997股。根据董事会安排，为确定股东有权出席并投票的资格，公司将于2026年6月23日至2026年6月26日暂停办理股份过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀授予董事股份购回授权，规模达已发行股本一成","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640594822","title":"云顶新耀：附属公司与Travere签署独家合作协议 预计获1.13亿美元前期付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2640594822","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640594822?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:10","pubTimestamp":1780402200,"startTime":"0","endTime":"0","summary":"6月2日，云顶新耀（01952）发布公告，本公司全资附属公司EverestMedicines(Singapore)Pte.Ltd.（授权人）与TravereTherapeutics,Inc.（Travere）（纳斯达克全球市场上市公司，股份代号为TVTX）订立独家许可与合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023757752413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640175209","title":"云顶新耀(01952)向Travere授予独家授权以开发及商业化肾病新药civorebrutinib 预收1.125亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2640175209","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640175209?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:05","pubTimestamp":1780398303,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 公布，于2026年6月2日，公司全资附属公司Everest Medicines  Pte.Ltd.(授权人)与Travere Therapeutics,Inc.订立独家许可与合作协议，据此，授权人将向Travere授予一项独家、全球性的授权，以开发及商业化civorebrutinib。交割将于满足特定先决条件及监管程序后发生，授权人最终达成的里程碑付款金额仍存在不确定性。Civorebrutinib有潜力成为一款涵盖多个适应症的产品，用于多种免疫介导的肾脏疾病。此项授权交易将加速civorebrutinib的全球开发及商业化进程，为全球患者提供创新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)向Travere授予独家授权以开发及商业化肾病新药civorebrutinib 预收1.125亿美元首付款","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639446656","title":"港股异动 | 云顶新耀(01952)现涨超6% 耐赋康23项最新研究成果将亮相ERA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639446656","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639446656?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:33","pubTimestamp":1780036412,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀现涨超6%，截至发稿，涨5.85%，报30.42港元，成交额9913.67万港元。消息面上，云顶新耀宣布，耐赋康将在第63届欧洲肾脏协会大会上展示23项最新研究成果，包含11项口头报告和12项电子壁报。长江证券此前发布研报称，云顶新耀商业化能力已得到初步验证，正在通过加速BD引进后期及商业化资产，快速拓展治疗领域和收入来源，进入商业化驱动的良性循环，盈利能力持续改善，为实现其长期战略目标奠定了坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","VXUS","BK4588","BK4585","BK1161","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160827754","title":"异动解读 | 云顶新耀盘中大涨超5%，核心产品耐赋康多项研究成果将亮相国际大会","url":"https://stock-news.laohu8.com/highlight/detail?id=1160827754","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160827754?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:29","pubTimestamp":1780036143,"startTime":"0","endTime":"0","summary":"云顶新耀(01952)今日盘中大幅上涨5.08%，引起了市场的广泛关注。消息面上，公司宣布其核心产品耐赋康®（布地奈德肠溶胶囊，NEFECON®）将在第63届欧洲肾脏协会大会（ERA 2026）上展示多达23项最新研究成果。这一消息增强了市场对公司产品研发进展和未来商业潜力的信心，被认为是推动股价上涨的主要动力。据悉，这些研究成果包括11项口头报告和12项电子壁报，其中21项来自中国的真实世界研究，覆盖了慢性肾脏病治疗的多个关键维度。重要研究成果在国际顶级学术会议上的集中展示，通常被视为产品临床价值获得认可的重要标志。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638589762","title":"云顶新耀艾曲莫德获韩国上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2638589762","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638589762?lang=zh_cn&edition=full","pubTime":"2026-05-25 10:05","pubTimestamp":1779674700,"startTime":"0","endTime":"0","summary":"南方财经5月25日电，港股创新药企云顶新耀（HKEX1952.HK）宣布，韩国食品药品安全部（MFDS）已正式批准艾曲莫德（VELSIPITY?，中国大陆中文商品名维适平?）的新药上市许可申请（NDA），适用于治疗对传统治疗（如皮质类固醇或免疫抑制剂）或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253747851157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01952","BK1583","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637366234","title":"云顶新耀：康桥资本斥资1920万港元购买60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637366234","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637366234?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:56","pubTimestamp":1779411360,"startTime":"0","endTime":"0","summary":"5月22日，云顶新耀（01952）发布公告，公司主要股东康桥资本于2026年5月20日至5月21日期间，市场购买了60万股公司普通股，总代价约为1920万港元，平均价格约为每股31.91港元。自2025年12月以来，康桥资本及董事已在市场上购买超过306万股股份，总代价超过1.14亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223745963917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637685053","title":"云顶新耀(01952)获主要股东康桥资本增持60.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637685053","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637685053?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:06","pubTimestamp":1779404781,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)发布公告，董事会获非执行董事、董事会荣誉主席兼本公司主要股东傅唯先生(傅先生)告知，自2026年5月20日至2026年5月21日期间，康桥资本(作为本公司主要股东)于市场购入60.05万股本公司普通股(股份)，总代价约为1920万港元，平均价格约为每股股份31.91港元。自2025年12月以来，康桥资本及董事已于市场购入超过306.2万股股份，总代价超过1.138亿港元。董事会认为，购入股份反映本公司董事及主要股东对本公司未来前景及长远发展的坚定信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111006226","title":"云顶新耀获CBC集团大举增持：两日斥资1920万港元购入60.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1111006226","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111006226?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:03","pubTimestamp":1779404597,"startTime":"0","endTime":"0","summary":"在5月20日至21日期间，CBC集团以每股31.91港元的价格，购入了云顶新耀共计60.05万股股份，总涉资额约达1920万港元。此次增持行动凸显了投资方对公司前景的信心。\n此次交易的平均价格与近期市场表现相呼应，反映了机构投资者在当前市场环境下对云顶新耀的估值判断。大额资金的注入，往往被视为对公司基本面和未来增长潜力的积极认可。\n资本市场中，重要股东的增持行为通常向市场传递出积极信号，可能影响其他投资者的决策。此次交易完成后，市场将密切关注云顶新耀后续的业务进展与股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635697722","title":"云顶新耀(01952)获董事兼主要股东傅唯增持66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635697722","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635697722?lang=zh_cn&edition=full","pubTime":"2026-05-15 07:11","pubTimestamp":1778800314,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)发布公告，公司董事会获非执行董事、董事会荣誉主席兼公司主要股东傅唯先生告知，于2026年5月14日，傅先生透过其控制的公司于市场购入66万股公司普通股，总代价约为2070万港元，平均价格约为每股股份31.25港元。据傅先生表示，彼透过场内收购方式购入股份，乃基于其对公司未来前景及长远发展的坚定信心。在遵守适用法律及法规的前提下，傅先生不排除在适当时候进一步增持其于公司股份的可能性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0791},{"period":"1month","weight":-0.1481},{"period":"3month","weight":-0.2496},{"period":"6month","weight":-0.3587},{"period":"1year","weight":-0.4132},{"period":"ytd","weight":-0.2439}],"compareEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0502},{"period":"6month","weight":-0.0346},{"period":"1year","weight":0.0363},{"period":"ytd","weight":-0.038}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.243847},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}